StarZero All shows Try the podcast clipper →

Apr 26, 2017 · 20m · top-founders

641: He Has $25B In Medical Tech Exits, $2B Raised, He's Sitting On PhotoTherapy $1b+ Bet Now with CEO Jim Sweeney

Nathan Latka · 10m spoken Jim Sweeney · 7m spoken
0:00 / 0:00

gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions

In this episode of The Top, host Nathan Latka interviews prolific healthcare entrepreneur Jim Sweeney to discuss his $25 billion track record in exits and the market opportunity for his connected at-home phototherapy venture, Clarify Medical.

How this conversation actually went

Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. Nathan holds 58.5% of the talking time here. How this is scored →

Nathan as informed peer 2.4 Guest teaching 2.4 Guest disagreement 0.8 Nathan pushing back 2.2
05100:0010:0020:001:11–4:40 · Nathan as informed peer 2/10 Introducing Jim Sweeney and Medical Tech Exits Nathan introduces Sweeney's background and asks baseline questions about Clarify Medical's phototherapy market and smart connected device. Sweeney provides standard high-level medical context regarding skin disease treatment.4:40–7:34 · Nathan as informed peer 3/10 Career Milestones and the McGaw Labs Buyout Nathan inquires about Sweeney's prior corporate history, specifically his leveraged buyout of McGaw Labs. Sweeney explains how he leveraged insider knowledge to beat out 11 other bidders and turned all 4,000 employees into shareholders.7:34–11:19 · Nathan as informed peer 2/10 Direct-to-Consumer Model and Healthcare Policy Shifts Sweeney details the commercial pricing model of the device and explains how lack of doctor compensation and healthcare policy shifts forced a direct-to-consumer approach. Nathan asks follow-up questions regarding macro healthcare trends and patient expenses.11:19–14:34 · Nathan as informed peer 4/10 Fundraising, Financial Metrics, and Billion-Dollar Valuation Nathan probes into convertible note terms, valuation methodologies, and unit production economics. When Sweeney declines to disclose hardware manufacturing costs, Nathan pushes on COGS dynamics and target margins.14:34–18:13 · Nathan as informed peer 1/10 Sponsor Message: Managing Finances with FreshBooks Nathan delivers a FreshBooks sponsorship spot before running through the standard Famous Five closing questions. Sweeney gives brief answers about sleep, mentors, and government intervention in healthcare.1:11–4:40 · Guest teaching 2/10 Introducing Jim Sweeney and Medical Tech Exits Nathan introduces Sweeney's background and asks baseline questions about Clarify Medical's phototherapy market and smart connected device. Sweeney provides standard high-level medical context regarding skin disease treatment.4:40–7:34 · Guest teaching 3/10 Career Milestones and the McGaw Labs Buyout Nathan inquires about Sweeney's prior corporate history, specifically his leveraged buyout of McGaw Labs. Sweeney explains how he leveraged insider knowledge to beat out 11 other bidders and turned all 4,000 employees into shareholders.7:34–11:19 · Guest teaching 3/10 Direct-to-Consumer Model and Healthcare Policy Shifts Sweeney details the commercial pricing model of the device and explains how lack of doctor compensation and healthcare policy shifts forced a direct-to-consumer approach. Nathan asks follow-up questions regarding macro healthcare trends and patient expenses.11:19–14:34 · Guest teaching 3/10 Fundraising, Financial Metrics, and Billion-Dollar Valuation Nathan probes into convertible note terms, valuation methodologies, and unit production economics. When Sweeney declines to disclose hardware manufacturing costs, Nathan pushes on COGS dynamics and target margins.14:34–18:13 · Guest teaching 1/10 Sponsor Message: Managing Finances with FreshBooks Nathan delivers a FreshBooks sponsorship spot before running through the standard Famous Five closing questions. Sweeney gives brief answers about sleep, mentors, and government intervention in healthcare.1:11–4:40 · Guest disagreement 0/10 Introducing Jim Sweeney and Medical Tech Exits Nathan introduces Sweeney's background and asks baseline questions about Clarify Medical's phototherapy market and smart connected device. Sweeney provides standard high-level medical context regarding skin disease treatment.4:40–7:34 · Guest disagreement 0/10 Career Milestones and the McGaw Labs Buyout Nathan inquires about Sweeney's prior corporate history, specifically his leveraged buyout of McGaw Labs. Sweeney explains how he leveraged insider knowledge to beat out 11 other bidders and turned all 4,000 employees into shareholders.7:34–11:19 · Guest disagreement 1/10 Direct-to-Consumer Model and Healthcare Policy Shifts Sweeney details the commercial pricing model of the device and explains how lack of doctor compensation and healthcare policy shifts forced a direct-to-consumer approach. Nathan asks follow-up questions regarding macro healthcare trends and patient expenses.11:19–14:34 · Guest disagreement 3/10 Fundraising, Financial Metrics, and Billion-Dollar Valuation Nathan probes into convertible note terms, valuation methodologies, and unit production economics. When Sweeney declines to disclose hardware manufacturing costs, Nathan pushes on COGS dynamics and target margins.14:34–18:13 · Guest disagreement 0/10 Sponsor Message: Managing Finances with FreshBooks Nathan delivers a FreshBooks sponsorship spot before running through the standard Famous Five closing questions. Sweeney gives brief answers about sleep, mentors, and government intervention in healthcare.1:11–4:40 · Nathan pushing back 1/10 Introducing Jim Sweeney and Medical Tech Exits Nathan introduces Sweeney's background and asks baseline questions about Clarify Medical's phototherapy market and smart connected device. Sweeney provides standard high-level medical context regarding skin disease treatment.4:40–7:34 · Nathan pushing back 2/10 Career Milestones and the McGaw Labs Buyout Nathan inquires about Sweeney's prior corporate history, specifically his leveraged buyout of McGaw Labs. Sweeney explains how he leveraged insider knowledge to beat out 11 other bidders and turned all 4,000 employees into shareholders.7:34–11:19 · Nathan pushing back 2/10 Direct-to-Consumer Model and Healthcare Policy Shifts Sweeney details the commercial pricing model of the device and explains how lack of doctor compensation and healthcare policy shifts forced a direct-to-consumer approach. Nathan asks follow-up questions regarding macro healthcare trends and patient expenses.11:19–14:34 · Nathan pushing back 5/10 Fundraising, Financial Metrics, and Billion-Dollar Valuation Nathan probes into convertible note terms, valuation methodologies, and unit production economics. When Sweeney declines to disclose hardware manufacturing costs, Nathan pushes on COGS dynamics and target margins.14:34–18:13 · Nathan pushing back 1/10 Sponsor Message: Managing Finances with FreshBooks Nathan delivers a FreshBooks sponsorship spot before running through the standard Famous Five closing questions. Sweeney gives brief answers about sleep, mentors, and government intervention in healthcare.

speaking balance: gold is Nathan, purple is the guest (3 minute bins)

0:00 · Nathan 93.7% · guest 6.3%0:00 · Nathan 93.7% · guest 6.3%3:00 · Nathan 36% · guest 64%3:00 · Nathan 36% · guest 64%6:00 · Nathan 26.1% · guest 73.9%6:00 · Nathan 26.1% · guest 73.9%9:00 · Nathan 29.1% · guest 70.9%9:00 · Nathan 29.1% · guest 70.9%12:00 · Nathan 61.6% · guest 38.4%12:00 · Nathan 61.6% · guest 38.4%15:00 · Nathan 70.1% · guest 29.9%15:00 · Nathan 70.1% · guest 29.9%18:00 · Nathan 98.8% · guest 1.2%18:00 · Nathan 98.8% · guest 1.2%
Sharpest disagreement ▶ 13:00 Sweeney refuses to disclose hardware unit economics

When Nathan asks what the device costs to manufacture, Sweeney outright refuses to share the numbers before admitting they currently lose money on each unit.

 Hardest push from Nathan ▶ 13:17 Nathan pushes back on hidden COGS

Nathan refuses to let Sweeney's deflection pass, explaining that entrepreneurs typically hide COGS either when deeply unprofitable or hiding proprietary low costs.

 Biggest teaching moment ▶ 8:38 Sweeney educates on biologic vs phototherapy economics

Sweeney explains how alternative biologic treatments cost up to $100k with severe side effects, explaining why phototherapy remains underutilized due to physician compensation structures.

 Nathan holds their own ▶ 12:28 Nathan breaks down convertible debt terms

Nathan demonstrates financial literacy by instantly translating Sweeney's financing explanation into exact convertible note debt mechanics and interest terms.
the scores for every segment, with the reasoning behind each
ChapterTopicNathan as informed peerGuest teachingGuest disagreementNathan pushing backWhy
Introducing Jim Sweeney and Medical Tech Exits 2201 Nathan introduces Sweeney's background and asks baseline questions about Clarify Medical's phototherapy market and smart connected device. Sweeney provides standard high-level medical context regarding skin disease treatment.
Career Milestones and the McGaw Labs Buyout 3302 Nathan inquires about Sweeney's prior corporate history, specifically his leveraged buyout of McGaw Labs. Sweeney explains how he leveraged insider knowledge to beat out 11 other bidders and turned all 4,000 employees into shareholders.
Direct-to-Consumer Model and Healthcare Policy Shifts 2312 Sweeney details the commercial pricing model of the device and explains how lack of doctor compensation and healthcare policy shifts forced a direct-to-consumer approach. Nathan asks follow-up questions regarding macro healthcare trends and patient expenses.
Fundraising, Financial Metrics, and Billion-Dollar Valuation 4335 Nathan probes into convertible note terms, valuation methodologies, and unit production economics. When Sweeney declines to disclose hardware manufacturing costs, Nathan pushes on COGS dynamics and target margins.
Sponsor Message: Managing Finances with FreshBooks 1101 Nathan delivers a FreshBooks sponsorship spot before running through the standard Famous Five closing questions. Sweeney gives brief answers about sleep, mentors, and government intervention in healthcare.

Statements from this episode (12)

Disclosure
Clarify Medical plans online direct-to-patient launch after FDA clearance
“We've developed a device and are seeking FDA clearance in the next few months. That will enable people to self-treat at home. Using a smart app, we're able to surveil what they're doing, prevent them from over-utilizing a device, communicate all of that inform…”
Jim Sweeney Apr 26, 2017 ▶ 3:15
Assertion Supported
Sweeney: Founded healthcare companies have generated over $25B in exit value
“A little north of twenty-five billion.”
Jim Sweeney Apr 26, 2017 ▶ 4:57
Assertion Not publicly verifiable
Sweeney: McGaw Labs buyout delivered a 6.5x ROI within three years
“Substantial market share from competitors, which led to about a six and a half time, ah, ROI for investors in three years.”
Jim Sweeney Apr 26, 2017 ▶ 6:14
Assertion Not publicly verifiable
Sweeney: Granted equity to all 4,000 McGaw Labs employees after buyout
“The other thing importantly I did was I made every single employee in a sixty-year-old company about 4000 employees. Every single employee became a shareholder.”
Jim Sweeney Apr 26, 2017 ▶ 6:59
Disclosure
Clarify Medical plans to sell its phototherapy device for $800 or $39/month
“It'll sell for 800 dollars or about 70% of the people we polled would rather buy it on a Monthly basis, it'll be about 39 dollars a month to lease it or to buy it on over time.”
Jim Sweeney Apr 26, 2017 ▶ 7:47
Assertion Supported
Sweeney: Alternative biologic and therapeutic drugs cost up to $100k annually
“Up to a 100,000 dollars a year with biologic and therapeutic drugs that also have horrific side effects.”
Jim Sweeney Apr 26, 2017 ▶ 8:31
Prediction Not checkable as stated
Sweeney: Out-of-pocket costs will force healthcare to treat patients as customers
“The bad news is that people are going to have to start reaching in their pocket to pay for things much more than they ever envisioned in the past. And the good news is as a result of that, they're starting to be viewed for the first time since Medicare was pas…”
Jim Sweeney Apr 26, 2017 ▶ 10:43
Disclosure
Sweeney: Clarify Medical raised $6M and seeks $12M to $15M more
“We've got about six million dollars invested and I'm looking to raise another 12 to fifteen million in the next few months.”
Jim Sweeney Apr 26, 2017 ▶ 11:35
Insight
Sweeney: Medical tech companies typically exit at 15 to 20x EBITDA
“And these companies exit values would typically be 15 to 20 times EBITDA.”
Jim Sweeney Apr 26, 2017 ▶ 12:09
Disclosure
Sweeney: Clarify Medical device currently costs more to make than sell
“Well, the truth is that the moment it'll cost us more to make than we'll sell it for. That's a function of volume, obviously.”
Jim Sweeney Apr 26, 2017 ▶ 13:09
Prediction Open · timeframe Apr 2022
Sweeney: Clarify Medical will exit between $500 million and $1 billion
“Well, I don't do companies that aren't, don't hit a billion, so that's my goal. I'd say, you know, it'll be somewhere between half a billion and a billion on exit value.”
Jim Sweeney Apr 26, 2017 ▶ 14:25
Opinion
Sweeney: Government intervention in healthcare has been deeply traumatic
“Yes, I wish I knew that the government would have the amount of influence on healthcare that they have today. I didn't foresee that being as traumatic as it's been.”
Jim Sweeney Apr 26, 2017 ▶ 17:12
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 2,600 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.

Try the podcast clipper Learn more